EP0334244A3 — Bradykinin antagonist peptides
Assigned to Procter and Gamble Co · Expires 1991-05-29 · 35y expired
What this patent protects
The present invention involves nona- or larger bradykinin antagonist peptides characterized by the structure: H-L-Q-T-U-V-W-X-Y-Z-Arg-OH where certain amino acid residues of the nonapeptide hormone bradykinin or other substituted analogs of bradykinin are altered as follow…
USPTO Abstract
The present invention involves nona- or larger bradykinin antagonist peptides characterized by the structure: H-L-Q-T-U-V-W-X-Y-Z-Arg-OH where certain amino acid residues of the nonapeptide hormone bradykinin or other substituted analogs of bradykinin are altered as follows: either position 2, position 3, or both consist of a L-acidic, L-amide or L-hydroxamate amino acid residue; position 7 consists of a D-aromatic amino acid residue; and position 4 preferably consists of a L-aliphatic or a D-cyclic amino acid residue.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.